Literature DB >> 11867372

The direct myocardial effects of xenon in the dog heart in vivo.

Benedikt Preckel1, Dirk Ebel, Jost Müllenheim, Jan Frässdorf, Volker Thämer, Wolfgang Schlack.   

Abstract

UNLABELLED: Xenon has minimal hemodynamic side effects, but no data are available on its direct myocardial effects in vivo. We examined myocardial function during the global and regional administration of xenon in the dog heart. Anesthetized (midazolam/piritramide) dogs (n = 8) were instrumented for measurement of left ventricular pressure, cardiac output, and blood flow in the left anterior descending coronary artery (LAD) and circumflex coronary artery. Regional myocardial function was assessed by sonomicrometry in the antero-apical and the postero-basal wall. Hemodynamics were recorded during baseline conditions and during inhalation of 50% or 70% xenon, respectively. Subsequently, a bypass containing a membrane oxygenator was installed from the carotid artery to the LAD, allowing xenon administration only to the LAD-dependent myocardium. No changes in myocardial function were observed during inhalation of xenon. The regional administration of 50% xenon had no significant effect on regional myocardial function (systolic wall thickening and mean velocity of systolic wall thickening). Seventy percent xenon reduced systolic wall thickening by 7.2% +/- 4.0% and mean velocity of systolic wall thickening by 8.2% +/- 4.0% in the LAD-perfused area (P < 0.05). There were no changes of global hemodynamics, coronary blood flow, and regional myocardial function in the circumflex coronary artery-dependent myocardium. Xenon produces a small but consistent direct negative inotropic effect in vivo. IMPLICATIONS: Regional administration of xenon direct to the left anterior descending-perfused myocardium resulted in a small but consistent negative inotropic effect of the noble gas in the dog heart in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867372     DOI: 10.1097/00000539-200203000-00012

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

Review 1.  Noble gases as cardioprotectants - translatability and mechanism.

Authors:  Kirsten F Smit; Nina C Weber; Markus W Hollmann; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Mechanisms of xenon- and isoflurane-induced preconditioning - a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway.

Authors:  Nina C Weber; Octavian Toma; Jessica I Wolter; Nicole M Wirthle; Wolfgang Schlack; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK.

Authors:  Nina C Weber; Octavian Toma; Jessica I Wolter; Detlef Obal; Jost Müllenheim; Benedikt Preckel; Wolfgang Schlack
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

4.  Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats.

Authors:  Yasushi Mio; Yon Hee Shim; Ebony Richards; Zeljko J Bosnjak; Paul S Pagel; Martin Bienengraeber
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

5.  Safety and feasibility of xenon as an adjuvant to sevoflurane anaesthesia in children undergoing interventional or diagnostic cardiac catheterization: study protocol for a randomised controlled trial.

Authors:  Sarah Devroe; Jurgen Lemiere; Marc Van de Velde; Marc Gewillig; Derize Boshoff; Steffen Rex
Journal:  Trials       Date:  2015-03-04       Impact factor: 2.279

Review 6.  Noble Gases Therapy in Cardiocerebrovascular Diseases: The Novel Stars?

Authors:  Jiongshan Zhang; Wei Liu; Mingmin Bi; Jinwen Xu; Hongzhi Yang; Yaxing Zhang
Journal:  Front Cardiovasc Med       Date:  2022-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.